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Abstract 
Background: Evidence for distinct asthma phenotypes and their overlap is becoming increasingly relevant to iden-
tify personalized and targeted therapeutic strategies. In this study, we aimed to describe the overlap of five commonly 
reported asthma phenotypes in US adults with current asthma and assess its association with asthma outcomes.
Methods: Data from the National Health and Nutrition Examination Surveys (NHANES) 2007–2012 were used 
(n = 30,442). Adults with current asthma were selected. Asthma phenotypes were: B-Eos-high [if blood eosinophils 
(B-Eos) ≥ 300/mm3]; FeNO-high (FeNO ≥ 35 ppb); B-Eos&FeNO-low (B-Eos < 150/mm3 and FeNO < 20 ppb); asthma 
with obesity (AwObesity) (BMI ≥ 30 kg/m2); and asthma with concurrent COPD. Data were weighted for the US popu-
lation and analyses were stratified by age (< 40 and ≥ 40 years old).
Results: Of the 18,619 adults included, 1059 (5.6% [95% CI 5.1–5.9]) had current asthma. A substantial overlap was 
observed both in subjects aged < 40 years (44%) and ≥ 40 years (54%). The more prevalent specific overlaps in both 
age groups were AwObesity associated with either B-Eos-high (15 and 12%, respectively) or B-Eos&FeNO-low asthma 
(13 and 11%, respectively). About 14% of the current asthma patients were “non-classified”. Regardless of phenotype 
classification, having concomitant phenotypes was significantly associated with (adjusted OR, 95% CI) ≥ 2 controller 
medications (2.03, 1.16–3.57), and  FEV1 < LLN (3.21, 1.74–5.94), adjusted for confounding variables.
Conclusions: A prevalent overlap of commonly reported asthma phenotypes was observed among asthma patients 
from the general population, with implications for objective asthma outcomes. A broader approach may be required 
to better characterize asthma patients and prevent poor asthma outcomes.
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Background
Profiling asthma phenotypes is becoming increasingly 
relevant to choose the most appropriate therapeutic 
strategy for individual patients, and to provide optimal 
improvement of disease control and quality of life [1, 2].
The predominant pathophysiological mechanism of 
asthma is type 2-mediated, associated with atopy and 
eosinophilic inflammation [3, 4]. However, it has been 
shown that asthma is a heterogeneous disease that 
involves other mechanisms that are not so well under-
stood and respond poorly to corticosteroid therapy (e.g. 
non-type 2-mediated) [3, 5, 6].
There has been a recent rise in the number of stud-
ies that try to identify asthma phenotypes based on 
non-invasive type 2-markers, such as blood eosinophils 
(B-Eos) count, fraction of exhaled nitric oxide (FeNO), 
serum IgE, and/or serum periostin [7–10]. Moreover, 
there appears to be an additive role of biomarkers, such 
as B-Eos and FeNO, in relation to recent asthma morbid-
ity [7, 11, 12].
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However, there is little information regarding the 
appropriate use of these biomarkers in asthma pheno-
type classification, particularly when a significant over-
lap occurs. Also, the importance of having concomitant 
asthma phenotypes for disease outcomes has scarcely 
been studied in the general population. This information 
may be useful to identify personalized and targeted ther-
apeutic strategies [13, 14].
Recently, an extensive overlap of asthma phenotypes 
was described [15]. However, only type 2-high, atopic, 
and eosinophilic asthma were examined. The extent of 
overlap with other phenotypes commonly reported in 
the literature, among adults with asthma from the gen-
eral population remains unknown. Asthma phenotypes 
are frequently reported in the literature according to the 
high levels of systemic and local type 2-markers (B-Eos 
high and FeNO-high, respectively) [1–4, 16–18]. How-
ever, other distinct subgroups of asthma phenotypes are 
increasingly being reported due to its characteristics 
of steroid therapy resistance and lack of inflammatory 
markers: e.g. subjects with asthma without evidence of 
type 2 inflammation (Th2-low phenotype); obese asth-
matic subjects (obesity-related asthma phenotype); and 
patients with asthma-COPD overlap syndrome [19–22].
Therefore, we hypothesized that if, in general popula-
tion, occurs a high proportion of overlap of commonly 
reported asthma phenotypes, there may be a need for 
improving the definition of asthma phenotypes. Addi-
tionally, asthma subjects with multiple phenotypes may 
have poorer asthma-related outcomes.
The aims of this study were to describe the propor-
tion of overlap of five commonly reported asthma phe-
notypes: asthma with obesity (AwObesity), asthma with 
concurrent COPD (AwCOPD), B-Eos-high, FeNO-high 
and B-Eos&FeNO-low asthma, and to examine the 
association of their overlap with asthma-related out-
comes, using population-based data from the National 
Health and Nutrition Examination Surveys (NHANES), 
2007–2012.
Methods
Study design
The NHANES is a nationally representative survey of the 
civilian, non-institutionalized U.S. population that uses a 
complex stratified, multistage probability sampling. Fur-
ther details on NHANES survey design databases can 
be found in Additional file  1: Supplementary methods. 
The National Center for Health Statistics, Ethics Review 
Board approved NHANES protocol, and all participants 
gave written informed consent.
Subjects selection
Six survey years (NHANES 2007–2012) were analyzed, 
resulting in 30,442 individuals of all ages (Fig.  1). We 
included adults (≥ 18  years-old) with current asthma 
(n = 1059), defined by a positive answer to the ques-
tions: “Has a doctor ever told you that you have asthma?” 
together with “Do you still have asthma?”, and either 
“wheezing/whistling in the chest in the past 12 months” 
or “asthma attack in the past 12 months.”
Variables
Demographic characteristics, such as age, gender, body 
mass index (BMI), race/ethnicity, and educational sta-
tus were analyzed. B-Eos count, FeNO and spirometric 
measurements, collected at the NHANES Mobile Exami-
nation Center were also examined. A detailed descrip-
tion of the procedures can be found elsewhere [23–25]. 
FeNO and spirometric measurements not fulfilling ATS/
ERS recommendations [26, 27] were excluded (n = 653). 
After predicted values of basal  FEV1 and  FEV1/FVC were 
calculated [28], with a correction factor for ethnicity [29], 
abnormal lung function was defined if either one of them 
were less than the lower limit of normal (LLN), defined 
as lower fifth percentile of the reference population [30].
Prescription medications used last month were also 
analyzed [31]. More details regarding the inclusion of 
reliever and controller medications for asthma and the 
definitions of each asthma-related variable included in 
the analysis (asthma attack, asthma-related emergency 
department (ED) visit, work/school absenteeism, asthma 
symptoms, smoking status and rhinitis) are provided in 
the supplementary material (see Additional file 1: Supple-
mentary methods).
Asthma phenotypes definition
A B-Eos count ≥ 300/mm3 was used to define an B-Eos-
high asthma phenotype [32, 33], while FeNO-high was 
defined as FeNO ≥ 35  ppb [34]. Asthma patients with 
both B-Eos < 150/mm3 and FeNO < 20  ppb were catego-
rized as B-Eos&FeNO-low asthma [35]. Additionally, we 
considered subjects with either B-Eos-high or FeNO-
high as having “Type 2-high” asthma.
The AwObesity phenotype was defined by a 
BMI ≥ 30 kg/m2 in individuals with current asthma [36]. 
Finally, the AwCOPD phenotype was considered if par-
ticipants ≥ 40  years-old had concurrent asthma and 
COPD, defined by a positive answer to “Has a doctor ever 
told you that you have chronic bronchitis/emphysema”, 
with age of diagnosis ≥ 40 years and having self-reported 
smoking history (being either a current or ex-smoker) 
[37, 38].
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Statistical analysis
In accordance with the NHANES sampling design, the 
weights for each full sample 2-year mobile examination 
center were used to obtain weighted percentages adjusted 
to the US adult population.
Categorical variables were described as frequencies 
and weighted proportions, and continuous variables were 
described as median and first and third quartiles (Q1–
Q3). Chi square test and Mann–Whitney U-test were 
used to compare groups. To explore the association of 
concomitant (having at least 2 concurrent) phenotypes 
with each asthma-related outcome we performed mul-
tivariate logistic regression modelling. Separate models 
were run using each asthma-related outcome and abnor-
mal lung function as dependent variable and having mul-
tiple phenotypes as independent variables. Adjustments 
were also made for potential confounders: sex, age, race, 
current smoking and rhinitis. Adjusted odds ratios (aOR) 
with 95% confidence intervals (95% CI) were presented, 
and model fit was assessed using the svylogitgof function 
[39].
According to age (< 40 or ≥ 40  years-old), a four- or 
five-set Venn-Euler diagram was used to quantify the 
proportion of individuals with different asthma pheno-
types and to illustrate the overlap.
The diagrams were created using R software version 
3.2.0 (“VennDiagram”, “venneuler” and “reshape2” pack-
ages) and all statistical analyses were performed in Stata 
version 13.1 (StataCorp, TX, USA), using the survey com-
mand to account for the complex sampling design and 
weights in the NHANES. The MI command was used to 
perform sensitivity analysis by multiple-imputation of 
missing values; however, to create the Venn-Euler dia-
grams, a listwise deletion for missing data was applied. A 
p value < 0.05 was considered statistically significant.
NHANES 2007-2008
Total sample 
(n=10,149)
NHANES 2009-2010
Total sample
(n=10,537)
NHANES 2011-2012
Total sample
(n=9756)
With data for phenotype 
classification
(n=634)
Missing data on main variables:
- FeNO (n=285)
- B-Eos (n=103)
- Chronic bronchitis/emphysema (n=121)
- Smoking history (n=59)
- BMI (n=50)
Adults (≥18 years old) with 
current asthma
(n=1059)
Exclusion:
- Subjects <18 years old (n=11,823)
- Adults with no current asthma (n=17,481)
- Missing data needed to classify current 
asthma (n=79)
X
X
Asthma phenotypes†:
- AwObesity: BMI ≥30kg/m2 (n=339)
- B-Eos-high: B-Eos ≥300/mm3 (n=237)
- B-Eos&FeNO-low: FeNO <20ppb + B-Eos <150/mm3 (n=157)
- FeNO-high: FeNO ≥35ppb (n=110)
- AwCOPD: chronic bronchitis/emphysema (age of diagnosis ≥40 years) + 
ever smoked ≥100 cigarettes (n=57)
Fig. 1 Flowchart of the study analysis. †Seventy-seven patients were considered “non-classified” (non-single and non-multiple phenotype)
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Results
Of the 18,619 adults included in NHANES 2007–2012 
datasets, 1059 (5.6% [95% CI 5.1–5.9]) had current 
asthma (Fig.  1). Of these, 63% were female, and the 
median (Q1–Q3) age was 48.0 (32.0–62.0) years. After 
excluding subjects with missing data on the main vari-
ables, 634 individuals were included for phenotype classi-
fication (Fig. 1). Despite having all information available, 
77 patients did not meet the criteria for any of the defined 
asthma phenotypes and were considered “non-classi-
fied”. These were non-obese subjects with asthma who 
did not meet the criteria for COPD, had B-Eos values 
ranging between 150 and 300/mm3, and FeNO ranging 
20–34 ppb.
Demographic characteristics of adults with current 
asthma included and excluded from the analysis and 
patients with single (n = 271) and multiple phenotypes 
(n = 286) are described in Table 1.
There is a female predominance in both groups (64 and 
66%, respectively). Subjects with multiple phenotypes 
were older (p = 0.003), had higher BMI (p < 0.001), were 
more often obese (p < 0.001) and ex-smokers (p = 0.003), 
and a higher proportion of patients were treated with 
inhaled corticosteroids (ICS) (p = 0.01), than those with 
only one phenotype. Females were more obese, regard-
less the number of concomitant asthma phenotypes (data 
not shown).
Phenotypes and overlap description
The weighted proportions of asthma phenotypes were (in 
descending order): 49% for AwObesity, 36% for B-Eos-
high asthma, 26% for B-Eos&FeNO-low asthma, 18% for 
FeNO-high asthma, and 8% for AwCOPD (Table 1).
Demographic and clinical characteristics among all 5 
asthma phenotypes and the “non-classified” group are 
described in Table 2.
There is a female predominance among all phenotypes, 
particularly in the B-Eos&FeNO-low (78%). Subjects with 
AwCOPD phenotype were the oldest group (median 
[Q1–Q3]: 61.0 [52.0–69.0] years-old), with the lowest 
proportion of individuals that had ≥ high school and low-
est  FEV1/FVC (0.63 [0.50–0.75]), comparing to the other 
phenotypes.
When categorized by age, < 40 (n = 227) and 
≥ 40 years-old (n = 330), the most prevalent phenotypes 
were AwObesity (42 and 53%, respectively) and B-Eos-
high asthma (34 and 37%). The less ones were FeNO-high 
asthma (18 and 19%) and AwCOPD (19% in the older 
group) (Fig. 2).
The areas of intersection in the four- and five-set Venn-
Euler diagrams revealed 5 and 12 overlapping categories, 
and proportions of 17 and 12% of non-classified asthma 
subjects, respectively.
In both diagrams, a substantial total overlap was 
observed: 44% in subjects < 40 years-old and 54% in sub-
jects ≥ 40 years-old. About 40% of the individuals in both 
age groups had two concomitant asthma phenotypes, 4% 
of the younger group had 3 concomitant phenotypes and 
13% of the older group had ≥ 3 (Table 3 and Fig. 2). Fur-
thermore, 1% of the older subjects had four concomitant 
asthma phenotypes: AwObesity, AwCOPD, FeNO-high, 
and B-Eos-high asthma.
The most prevalent overlaps in both groups (< 40 and 
≥ 40  years-old) were AwObesity together with either 
B-Eos-high (15 and 12%, respectively) or B-Eos&FeNO-
low asthma (13 and 11%) (Fig. 2).
Moreover, the proportions of subjects having 
AwObesity together with other phenotypes were high: 
53% for the B-Eos-high phenotype, 48% for AwCOPD, 
45% for the B-Eos&FeNO-low, and 44% for the FeNO-
high phenotype. Also, the proportion of individuals hav-
ing AwCOPD together with the B-Eos-high phenotype 
was high (36%), whereas the proportions were lower for 
the B-Eos&FeNO-low and the FeNO-high asthma phe-
notypes (15 and 10%, respectively) (data not shown).
In this population, only 12 and 15% of asthma subjects 
(< 40 and ≥ 40  years-old, respectively) with high B-Eos 
count had a concomitant high FeNO values (Fig.  2). 
Moreover, the two biomarkers were non-congruent 
across cut-offs. For example, when comparing groups 
with B-Eos count < 150/mm3 and 150–300/mm3, the pro-
portion of asthma subjects having low FeNO (< 20 ppb), 
was not significantly different (Additional file  2: Table 
S1).
Associations between asthma‑related outcomes 
and phenotype overlap
A comparison of the clinical characteristics of partici-
pants with one, two or three or more asthma phenotypes, 
stratified by age, is presented in Table  3 and no signifi-
cant differences were observed in any age groups with 
regard to asthma attacks, asthma-related ED, ≥ 2 asthma 
symptoms, and use of ≥ 1 reliever. In the older group, the 
proportion of individuals with work/school absenteeism, 
≥ 2 controller medications and with  FEV1/FVC < LLN 
was significantly higher in participants with concomi-
tant phenotypes than in those with a single phenotype 
(Table 3). In both age groups, the proportion of patients 
with  FEV1 < LLN was significantly higher when partici-
pants presented multiple phenotypes, as well as they pre-
sented lower median  FEV1% predicted values.
When analyzing the asthma-related outcomes in sub-
jects with a single phenotype with those having specific 
combination of asthma phenotypes, the overall findings 
were that subjects having multiple phenotypes had sig-
nificantly higher proportion of using ≥ 1 reliever and ≥ 2 
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controller medications and had decreased lung function, 
with the exception of those with the B-Eos&FeNO-low 
phenotype combined with any of the other phenotypes 
(Additional file  3: Table S2, and Additional file  4: Table 
S3).
Moreover, a lower proportion of subjects reporting 
asthma attacks was observed in subjects with AwObesity 
and either FeNO-high (26%) or AwCOPD (20%), com-
pared to those with a single phenotype (67%) (Additional 
file  3: Table S2). Subjects with concomitant AwCOPD 
and B-Eos&FeNO-low phenotypes had the lowest 
Table 1 Characteristics of adults with current asthma: included and excluded from phenotype classification, and strati-
fied by single or multiple phenotypes
Data presented as absolute numbers and proportions weighted for the U.S. population. p values < 0.05 are presented in italic
Yrs years, BMI body mass index, Q1 first quartile, Q3 third quartile, BMI body mass index, AwObesity Asthma with obesity, AwCOPD Asthma with concurrent COPD
* Chi square test or Mann–Whitney U-test was used
† Seventy seven subjects included in the “non-classified” group were considered as missing
‡ Prescribed medication taken in the past 30 days
§ Alone or in combination with long-acting inhaled β2-agonist
|| Included long-acting inhaled β2-agonist (without corticosteroids), leukotriene inhibitors, and mast cell stabilizers
**Short-acting β2-agonist and/or anticholinergic
†† Subjects with non-single and non-multiple asthma phenotype
Demographic characteristics
n (wt%)
Included subjects
n = 634
Excluded subjects
n = 425
p value* Single  phenotype†
n = 271
Multiple  phenotypes†
n = 286
p value*
Female gender 410 (63) 261 (64) 0.93 174 (64) 192 (66) 0.68
Age (yrs), median (Q1–Q3) 44.0 (31.0–57.0) 48.9 (33.7–68.0) < 0.001 42.0 (30.0–55.0) 47.5 (34.0–60.0) 0.003
BMI (kg/m2), median (Q1–Q3) 30.8 (25.4-35.9) 31.4 (24.4-35.7) 0.99 28.7 (24.2–35.0) 33.7 (30.7–39.0) < 0.001
Obesity status
 Underweight (≤ 18.4 kg/m2) 2 (0.3) 13 (4) < 0.001 1 (0.2) 1 (0.5) 0.41
 Normal (18.5–24.9 kg/m2) 142 (25) 98 (27) 0.44 78 (30) 20 (8) < 0.001
 Overweigh (25–29.9 kg/m2) 151 (26) 77 (19) 0.07 80 (32) 38 (15) < 0.001
 Obese (≥ 30 kg/m2) 339 (49) 187 (49) 0.94 112 (38) 227 (77) < 0.001
Race and/or ethnicity
 Hispanic 105 (8) 85 (10) 0.30 38 (8) 56 (9) 0.24
 Non-Hispanic white 323 (74) 184 (63) 0.005 135 (72) 138 (72) 0.93
 Non-Hispanic black 167 (14) 117 (18) 0.03 76 (14) 81 (16) 0.71
 Other Race 39 (4) 39 (7) 0.06 22 (6) 11 (3) 0.11
Smoking status
 Current smoker 199 (29) 114 (32) 0.40 89 (31) 87 (27) 0.46
 Ex-smoker 163 (29) 98 (23) 0.13 56 (20) 89 (36) 0.003
 Non-smoker 272 (43) 154 (45) 0.53 126 (49) 110 (37) 0.02
Education
 ≥ High school 478 (84) 225 (69) < 0.001 205 (86) 209 (81) 0.13
Asthma-related  medication‡
 Reliever medication** 276 (41) 202 (48) 0.16 113 (37) 132 (47) 0.10
 Oral corticosteroids 33 (8) 29 (3) 0.001 12 (3) 15 (4) 0.75
 Inhaled  corticosteroids§ 153 (25) 122 (30) 0.14 55 (19) 81 (32) 0.01
 Other control  medications|| 53 (9) 63 (14) 0.19 15 (8) 33 (10) 0.50
Asthma phenotype
 AwObesity 339 (49) – 112 (38) 227 (76) < 0.001
 B-Eos-high 237 (36) – 61 (22) 176 (62) < 0.001
 B-Eos&FeNO-low 157 (26) – 74 (30) 83 (30) 0.95
 FeNO-high 110 (18) – 18 (8) 92 (34) < 0.001
 AwCOPD 57 (8) – 6 (2) 51 (17) < 0.001
 Non-classified†† 77 (14) – – –
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proportion of ≥ 2 asthma symptoms (20%), but had the 
highest proportion of using ≥ 1 reliever medication (84%) 
as well as having  FEV1 < LLN (71%).
In multivariate regression analysis, adjusting for co-
variables, having multiple phenotypes was significantly 
associated with using ≥ 2 controller medications (aOR, 
95% CI 2.03, 1.16–3.57), and having reduced  FEV1 (3.21, 
1.73–5.94) (Table 4). However, no associations were seen 
with asthma attacks, asthma-related ED, ≥ 2 asthma 
symptoms, work/school absenteeism, use of reliever 
medication or  FEV1/FVC < LLN (Additional file 5: Table 
S4).
Furthermore, subjects aged ≥ 40 years-old, had signifi-
cantly higher odds of using ≥ 2 controller medications 
and having  FEV1 < LLN predicted, compared to 
those < 40  years-old, adjusted for covariates (Table  4). 
Being a current smoker was significantly associated 
with using ≥ 1 reliever medication (1.95, 1.35–2.83) and 
with reduced lung function:  FEV1 < LLN predicted (2.01, 
1.21–3.33) and  FEV1/FVC < LLN (2.02, 1.16–3.51) and 
not associated with any other asthma-related outcomes 
(Table 4 and Additional file 5: Table S4).
The association between having concomitant phe-
notypes and using multiple controller medications was 
consistent when considering oral corticosteroids (OCS) 
separated from other controller medications (1.87, 1.09–
3.21) (data not shown).
Table 2 Demographic and clinical characteristics among all 5 phenotypes and in the “Non-classified” group
Data presented as absolute numbers and proportions weighted for the U.S. population
Yrs years, BMI body mass index, Q1 first quartile, Q3 third quartile, BMI body mass index, AwObesity Asthma with obesity, AwCOPD Asthma with concurrent (COPD), ED 
emergency-department, FEV1 Forced expiratory volume in 1 s, FEV1/FVC forced expiratory volume in 1 s and functional vital capacity ratio, LLN lower limit of normality
†† Subjects with non-single and non-multiple asthma phenotype
‡ Prescribed medication taken in the past 30 days
** Short-acting β2-agonist and/or anticholinergic
§ Alone or in combination with long-acting inhaled β2-agonist
Characteristics
n (wt%)
AwObesity
n = 339
B‑Eos‑high
n = 237
B‑Eos&FeNO‑low
n = 157
FeNO‑high
n = 110
AwCOPD
n = 57
Non‑classified††
n = 77
Female gender 366 (67) 196 (55) 138 (78) 78 (52) 71 (58) 44 (56)
Age (yrs), median (Q1–Q3) 48.0 (34.0–59.0) 47.0 (31.0–59.0) 41.0 (27.0–57.0) 45.0 (30.0–54.0) 61.0 (52.0–69.0) 39.0 (28.0–53.0)
BMI (kg/m2), median (Q1–Q3) 35.4 (32.5–40.4) 30.3 (25.9–36.8) 28.9 (24.2–33.0) 27.6 (24.9–33.4) 30.3 (25.1–35.1) 24.3 (22.8–27.5)
Race and/or ethnicity
 Hispanic 94 (9) 78 (11) 30 (8) 29 (10) 18 (4) 11 (6)
 Non-Hispanic white 230 (65) 175 (73) 79 (69) 65 (75) 80 (81) 50 (86)
 Non-Hispanic black 177 (21) 74 (12) 62 (17) 38 (13) 27 (11) 10 (6)
 Other race 25 (5) 21 (4) 13 (6) 6 (2) 10 (4) 6 (2)
Smoking status
 Current smoker 150 (27) 104 (32) 48 (23) 18 (13) 65 (52) 23 (28)
 Ex-smoker 134 (27) 100 (32) 35 (25) 42 (39) 70 (48) 18 (30)
 Non-smoker 229 (45) 124 (35) 88 (51) 66 (49) 0 (0) 36 (42)
Education
 ≥ High school 358 (79) 227 (80) 125 (81) 102 (87) 73 (59) 64 (91)
Asthma-related  medication‡
 Reliever medication** 234 (42) 172 (51) 82 (44) 65 (46) 69 (57) 31 (36)
 Oral corticosteroids 36 (5) 17 (5) 4 (2) 10 (7) 15 (7) 2 (2)
 Inhaled  corticosteroids§ 144 (27) 103 (32) 36 (20) 36 (33) 60 (47) 17 (19)
Asthma-related outcomes
 Asthma attack 363 (68) 252 (74) 125 (68) 98 (71) 85 (63) 54 (75)
 Asthma-related ED 130 (27) 80 (23) 41 (23) 26 (13) 37 (32) 9 (8)
 > 2 asthma symptoms 311 (66) 199 (65) 92 (55) 80 (57) 90 (74) 42 (59)
 Work/school absenteeism 66 (18) 43 (16) 25 (18) 23 (14) 12 (20) 10 (14)
Lung function
 FEV1% predicted, median (Q1–Q3) 89.0 (75.6–99.2) 84.1 (75.2–95.4) 93.2 (83.8–100.8) 82.7 (75.9–95.4) 74.0 (62.9–90.1) 89.9 (80.5–103.5)
 FEV1/FVC, median (Q1–Q3) 0.77 (0.62–0.82) 0.74 (0.65–0.80) 0.79 (0.72–0.83) 0.72 (0.66–0.79) 0.63 (0.50–0.75) 0.76 (0.69–0.82)
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We also analyzed the potential bias of controller medi-
cations in the phenotype classification, particularly in 
the B-Eos-high and FeNO-high phenotypes (Additional 
file  6: Fig. S1). No significant differences in asthma-
related treatment were found between the phenotypes, 
with exception for a higher proportion of patients treated 
with ICS within the FeNO-high and B-Eos-high pheno-
types compared to those with B-Eos&FeNO-low pheno-
type (p = 0.03). When restricting to subjects with a single 
asthma phenotype no significant differences were found.
Moreover, sensitivity analyses showed that the propor-
tion of total overlap (weighted 53%), and the associa-
tions between having multiple phenotypes and asthma 
outcomes were similar when imputing all missing values 
(data not shown). The goodness-of-fit test revealed ade-
quate fitting for all regression models, except when using 
 FEV1/FVC < LLN as dependent variable (Additional file 5: 
Table S4) and no statistically significant interactions 
between co-variables were observed.
Discussion
We report a substantial overlap of commonly reported 
asthma phenotypes among adults with current asthma in 
a large population sample, with almost half of them hav-
ing two or more concomitant phenotypes. Furthermore, 
having multiple asthma phenotypes, regardless of their 
classification, was associated with poorer asthma out-
comes, particularly the use of more controller medication 
and reduced lung function.
These findings illustrate the complexity and unique 
features of the concomitant asthma phenotypes when 
categorizing asthma in adults, using only the “classical” 
(hypothesis-driven) approach, based on measures readily 
available in the clinic (such as non-invasive biomarkers 
and medical records).
Hypothesis-driven asthma phenotypes are usually 
based on single dimensions of the disease, such as clini-
cal symptoms, triggers, pathology or patterns of air-
way obstruction [16–18, 40–42]. However, evidence has 
shown that this approach is highly heterogenous, as it 
depends on the a priori assumptions and target popula-
tion [43–45]. Also, it is of note that the 77 subjects with 
asthma that could not be classified as having any of the 
studied phenotypes, supports the fact that there is a 
considerable number of asthma patients whose clinical 
phenotype is not easily classified (e.g. asthmatics with 
irreversible airflow obstruction, patients with similar 
airways symptoms but with different pattern of airway 
inflammation), suggesting the presence of sub-pheno-
types [1, 22, 44, 45].
In an attempt to explore the pathophysiology of specific 
asthma subgroups, and help stratify patients for targeted 
therapies, data-driven or unsupervised approaches (such 
as k-means, hierarchical clustering, partition-around-
medoids methods or latent class analysis) are being 
applied in airways disease to identify “novel” accurate 
and distinct phenotypes, taking into account the hetero-
geneity and multidimensional characteristics of the dis-
ease [8, 46–52].
Our study results seem to be in line with the view of 
those that argue for a combination of both hypothesis- 
and data-driven approaches as a way forward to pro-
gress our knowledge on asthma endotypes and clinical 
phenotypes in an iterative way [52–54]. The data-driven 
Fig. 2 Venn-Euler diagrams quantifying the overlap among the asthma phenotypes, stratified by age. Data presented in weighted percentages to 
the US population. The overlap between AwCOPD with FeNO-high asthma (0.1%) and the overlap between AwCOPD, FeNO-high, AwObesity and 
B-Eos-high (0.5%) phenotypes are not shown
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phenotypes studies obtained some of the phenotypes 
already defined by hypothesis-driven approaches (e.g. 
obese, non-eosinophilic asthmatics [8]; persistent airway 
inflammation [46]; low type-2 inflammation [49]; fixed 
obstructive, non-eosinophilic and neutrophilic [50]), 
but, importantly, they identified other phenotypes that 
differ by certain characteristics: clinical parameters [8, 
47–49], clinical response to treatment [46, 52], and air-
way inflammation [49, 51]. Therefore, further studies are 
required to compare and validate the asthma phenotypes 
obtained using different unsupervised methods.
The high overlap of asthma phenotypes seen in this 
study was similar to the findings of Tran et al. [15], who 
used datasets from previous NHANES surveys to evalu-
ate the overlap of asthma phenotypes. However, Tran 
et al. study focused on allergic asthma phenotypes, based 
on IgE levels, and was therefore limited to the 2005–2006 
survey that lacks data on FeNO. We provided a broader 
analysis of phenotypes that included not only the eosin-
ophil-based phenotype (associated more closely with 
IL-5-driven) and the one based on FeNO values (mostly 
dependent on IL-4/IL-13-driven) [12], but also other 
phenotypes not defined by biomarkers and in a much 
larger dataset.
In this study, we extended previous observations [7, 11] 
suggesting that FeNO and B-Eos count partially reflect 
different inflammatory pathways, representing a local 
and a systemic type 2-marker, respectively. We observed 
that only 12–15% of asthma subjects with high B-Eos 
count had concomitant high FeNO levels, in this popula-
tion. Also, a similar proportion of subjects with multiple 
phenotypes was obtained when considering the “Type 
2-high” phenotype, supporting the view that these two 
biomarkers are not interchangeable and that the use of 
both biomarkers in combination may allow for better tar-
geted and personalized treatment for at least certain sub-
sets of asthma patients [7, 10, 11].
The more prevalent combinations of phenotypes 
observed in this study were AwObesity together with 
either B-Eos-high or B-Eos&FeNO-low phenotypes. This 
supports the view that obesity-related asthma, despite 
often suggested to be a separate asthma phenotype asso-
ciated with non-eosinophilic airway inflammation [9, 55, 
56], may also be associated to eosinophilic inflammation.
Given the high prevalence in the US population, in this 
sample, obesity is likely to be a comorbidity, rather than 
the primary reason for asthma [57]; however, we defined 
the AwObesity phenotype as a separate group, since the 
interdependence on inflammatory markers to targeting 
different asthma therapies makes essential the accurate 
characterization of inflammation in obese asthmatic sub-
jects [19, 58]. In addition, the relevance of defining the 
AwObesity phenotype is supported by the data as the 
weighted proportion of overlap is similar when exclud-
ing AwObesity or B-Eos-high phenotype from the analy-
sis (data not shown). Moreover, the weighted proportion 
of subjects with “non-classified” asthma doubled when 
excluding the AwObesity phenotype (increasing to 32% 
in the < 40 years-old and 29% in ≥ 40 years old).
Having multiple asthma phenotypes was more com-
mon in older subjects and in non- and former- smokers; 
whether this is due to a general increase of comorbidi-
ties with age [58–60] and/or an interaction with environ-
mental factors [61] cannot be specifically addressed by 
this study design. Nevertheless, when interpreting these 
results one should bear in mind that AwCOPD is associ-
ated to older age and prior/current smoking while FeNO 
increases with age and decreases with smoking [62, 63].
Interestingly, subjects with a higher number of con-
comitant asthma phenotypes presented reduced lung 
function and this association remained when controlling 
for potential confounders by multiple regression analysis. 
This shows that having multiple phenotypes is indepen-
dently associated with reduced lung function, suggesting 
a cumulative effect of different disease processes.
Moreover, patients having several commonly reported 
asthma phenotypes had higher odds of using more con-
troller medications, supporting the view that these 
patients are those with more complex disease and higher 
asthma morbidity [9, 15]. This also suggests that these 
asthma patients have an inadequate response to pre-
scribed therapies, since lung function was reduced, and 
that they may represent a group of patients with the need 
for add-on treatment. However, the choice of specific 
Table 4 Regression models with significant associations 
between having multiple asthma phenotypes and asthma-
related outcomes, adjusted for co-variates
Multivariate logistic regression models adjusted for gender, age, race, current 
smoking and rhinitis. The aOR values with p < 0.05 are presented in italic
FEV1 forced expiratory volume in 1 s, LLN lower limit of normal, CI confidence 
interval, aOR adjusted odds ratio, χ2 Chi square goodness-of-fit
≥ 2 controller medi‑
cations
FEV1 < LLN
aOR 95% CI aOR 95% CI
Multiple versus single 
phenotype
2.03 1.16–3.57 3.21 1.74–5.94
Female gender 1.39 0.77–2.50 1.51 0.81–2.81
Age ≥ 40 yrs 3.01 1.52–5.95 2.55 1.29–5.03
Caucasian versus others 1.38 0.86–2.23 1.37 0.78–2.42
Current smoker versus 
non-/ex-smokers
1.02 0.52–2.02 2.01 1.21–3.33
Rhinitis 1.08 0.57–2.16 0.94 0.54–1.63
Goodness-of-fit test
 χ2 (p value) 0.86 (0.56) 0.80 (0.61)
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treatments, such as biological therapies, will be more dif-
ficult considering the complexity introduced by having 
multiple phenotypes.
The lack of significant associations between multiple 
phenotypes and the other asthma-related outcomes may 
be difficult to understand. A possible explanation could 
be that the prescribed medication is effective against 
asthma symptoms and attacks but less effective against 
(subclinical) processes that cause long-term reduction in 
lung function. However, the results could also be related 
to data collection methods, as lung function measure-
ment and the way medication use was ascertained, were 
less dependent on patient recall than the self-reported 
variables that were used for the outcomes with null 
results in the present study. Further studies should be 
done, adding the quantitative assessment of asthma 
attacks/asthma-related ED visits, and also including the 
age of asthma onset, that could have an influence on 
asthma-related outcomes.
This study has several limitations. First, because of its 
cross-sectional design, it was not possible to evaluate 
interactions between phenotypes over time in patients 
with concomitant phenotypes, nor was it possible to 
determine which phenotype occurred first. Second, 
although there were differences between the included 
and excluded groups in the variables age, BMI, non-His-
panic white/black subjects, having finished high school 
and OCS use, the majority were not used for pheno-
typic classification and did not affect the outcomes, as 
shown in sensitivity analysis. Third, as our asthma and 
COPD definitions were based on self-reported diagnosis, 
rather than relying on lung function tests, the acquired 
information is subject to recall bias and misclassifica-
tion. However, these definitions have been commonly 
used in NHANES reports [7, 11, 15] and have proven to 
be reasonably reliable [64, 65]. Moreover, we have used 
the most frequent combination of questions seen in epi-
demiological studies [65, 66], and we also included ques-
tions on recent wheeze and/or asthma attacks, which 
should reduce the risk of including individuals with-
out true disease. Also, we stratified the analysis by age 
(at 40 years), as used in other COPD studies [37, 67], in 
order to improve the clinical value into the interpreta-
tion of phenotyping data, as the overlap among asthma 
phenotypes will be different among those less than age 40 
and those older than 40 (with higher possibility of having 
COPD) [37]. Fourth, the lack of other biomarkers in the 
present NHANES years, prevented the analysis of other 
asthma phenotypes and the use of alternative definitions. 
However, we analyzed biomarkers of type 2-inflamma-
tion in both blood and exhaled air that previously have 
been shown to independently relate to asthma morbid-
ity [7, 11]. Fifth, as there is no consensual definition of 
biomarker-defined asthma phenotypes, we based our 
definitions on cut-offs used in previous studies to dis-
criminate patients in single asthma phenotypes [32–35], 
rather than on any reported specificity or sensitivity for 
predicting asthma morbidity or response to therapeutics 
[68, 69]. For high probability of eosinophilic inflamma-
tion, the cut-off value for FeNO has been suggested to 
be > 50  ppb for adults [70]. However, we chose a FeNO 
cut-off of 35  ppb, based on the mean baseline FeNO 
levels of patients included in randomized controlled tri-
als of anti-IL-13 treatment [33, 69]. In spite of using this 
lower cut-off, 77 subjects with current asthma could not 
be classified as having any of the predefined phenotypes, 
indicating the need for better, and probably personalized, 
cut-offs for biomarkers in asthma.
Furthermore, we could not demonstrate a clear effect 
of ongoing controller medication in the phenotypic clas-
sification in our data. No significant associations were 
observed, probably at least partially explained with the 
exclusion of the participants with ICS/OCS use < 48  h 
prior to the exhaled NO measurements. Also, contrary 
to the expected, we observed a higher proportion of 
patients treated with ICS/OCS within both B-Eos-high 
and FeNO-high phenotypes than the B-Eos&FeNO-low 
phenotype. A plausible explanation is that subjects with 
ongoing inflammation have more clear asthma, with 
more symptoms, and, thus, a higher need of treatment. 
B-Eos&FeNO-low asthma is a heterogeneous group with 
less need of controller treatment, and because the treat-
ment is ineffective, it may be that medication use and 
even prescription has been stopped.
Finally, even though we did not specifically analyze the 
overlap of asthma phenotypes in patients with severe 
asthma, the significant association between present-
ing more than one phenotype and being treated with 
multiple asthma controller medications suggests higher 
asthma severity in this subset [71]. Also, we did not 
consider individual environmental factors, such as air 
pollution and/or indoor allergens, that could influence 
asthma phenotypes. Further studies describing the over-
lap in patients with severe asthma and studies examin-
ing asthma patients exposed to different environmental 
factors, such as subjects who live in cities versus in rural 
areas are needed.
This study indicates that the overlap of commonly 
reported asthma phenotypes is observed also in non-
selected asthma patients from the general population. 
Our findings highlight the importance of classifying 
asthma patients with regard to applicable phenotypes, 
rather than using a single asthma phenotype, to enable 
the development of adequate targeted strategies to avoid 
lung function impairment. However, further data is 
required, such as that from higher order analysis, using 
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data-mining methods possibly combined with those that 
rely on predefined hypotheses. This synergy is expected 
to improve the knowledge on asthma phenotypes and, 
ultimately, to lead to more personalized treatment strate-
gies [53, 54].
Conclusions
In conclusion, a prevalent overlap of commonly reported 
phenotypes was observed in asthma patients identified 
from the general population. Subjects classified as having 
multiple phenotypes used more controller medications 
and had reduced lung function. Thus, the complexity 
and unique features of concomitant asthma phenotypes 
may require a broader data analysis approach, based on 
a combination of clinical information and biomarkers 
resulting in better characterization of patients. This could 
lead to better asthma outcomes, particularly preserved 
lung function.
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